Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01310387
Other study ID # PAIN_LCA_2011
Secondary ID
Status Completed
Phase Phase 3
First received February 1, 2011
Last updated February 4, 2016
Start date January 2011
Est. completion date June 2012

Study information

Verified date February 2016
Source Chonnam National University Hospital
Contact n/a
Is FDA regulated No
Health authority Korea: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This study is:

- A single-center, randomized, prospective controlled trial.

- To prove superiority of active pain management group compared to control group by the percent of pain intensity difference of outpatients with lung cancer pain.

- 204 patients will be recruited.


Description:

- The recruited patients in both group will be provided the education about pain-killer, and received medicines including opioids according to their numeric rating scale (NRS)

- Active management group will be provided additional telephone counseling and dosage modification by specialized nurse for cancer pain.

- The percent of pain intensity difference (%PID)

- PID = (NRS of visit 1 - NRS of visit 3)/NRS of visit 1


Recruitment information / eligibility

Status Completed
Enrollment 79
Est. completion date June 2012
Est. primary completion date January 2012
Accepts healthy volunteers No
Gender Both
Age group 20 Years to 80 Years
Eligibility Inclusion Criteria:

- Outpatients with lung cancer.

- The patients with uncontrolled lung cancer pain - more than and equal NRS 4 pain during previous 24 hours for background pain, or more than and equal 3 times/day for breakthrough painkiller medication.

- Over 20 year-old male or female.

- The patients can be able to received telephone counseling by investigator's decision.

Exclusion Criteria:

- Drug or alcohol abusers.

- Child-bearing women or pregnant women.

- The patients with moderate to severe psychiatric problems.

- The patients who have hypersensitivity to opioids.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care


Related Conditions & MeSH terms


Intervention

Behavioral:
Active pain management
Active pain management will be provided by specialized pain nurse, such as telephone counseling for toxicity control and opioid dose modification.

Locations

Country Name City State
Korea, Republic of Chonnam National University Hwasun Hospital Jeonnam

Sponsors (2)

Lead Sponsor Collaborator
Chonnam National University Hospital Janssen Korea, Ltd., Korea

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary The percent of pain intensity difference The percent of pain intensity difference (%PID)
%PID = (NRS of visit 1 - NRS of visit 3)/NRS of visit 1
visit 3 (6 to 8 weeks) No
Secondary Patients' satisfaction score about pain management Qustionnaire of 5-point scale visit 3 (6 to 8 weeks) No
Secondary Eastern Cooperative Oncology Group (ECOG) Performance score ECOG performance status: 0,1,2,3,4 visit 3 (6 to 8 weeks) No
Secondary Assessment of Korean Brief Pain Inventory score Qustionnaire; K-BPI(Korean Brief Pain Inventory) visit 3 (6 to 8 weeks) No
Secondary Investigator's global assessment score Qustionnaire of 5-point scale visit 3 (6 to 8 weeks) No
See also
  Status Clinical Trial Phase
Completed NCT03918538 - A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors N/A
Recruiting NCT05078918 - Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors N/A
Active, not recruiting NCT04548830 - Safety of Lung Cryobiopsy in People With Cancer Phase 2
Completed NCT04633850 - Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05583916 - Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05898594 - Lung Cancer Screening in High-risk Black Women N/A
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03575793 - A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Terminated NCT03275688 - NanoSpectrometer Biomarker Discovery and Confirmation Study
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT06052449 - Assessing Social Determinants of Health to Increase Cancer Screening N/A
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Not yet recruiting NCT06017271 - Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk